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Essentials 
• Correct duration of treatment after a first unprovoked venous thromboembolism (VTE) is 
unknown. 
• We assessed when restarting anticoagulation was worthwhile based on patient risk of 
recurrent VTE. 
• When the risk over a one-year period is 17.5%, restarting is cost-effective. 
• However, sensitivity analyses indicate large uncertainty in the estimates. 
 
Summary 
Background: Following at least three months of anticoagulation therapy after a first unprovoked 
Venous Thromboembolism (VTE), there is uncertainty about the duration of therapy. Further 
anticoagulation therapy reduces the risk of having a potentially fatal recurrent VTE but at the 
expense of a higher risk of bleeding which can also be fatal.  
Objective: An economic evaluation sought to estimate the long-term cost-effectiveness of using a 
decision rule for restarting anticoagulation therapy versus no extension of therapy in patients based 
on their risk of a further unprovoked VTE.  
Methods: A Markov patient-level simulation model was developed which adopted a lifetime time 
horizon with monthly time cycles and was from a UK National Health Service (NHS) /Personal Social 
Services (PSS) perspective. 
Results: Base case model results suggest that treating patients with a predicted one year VTE risk of 
17.5% or higher may be cost-effective if decision makers are willing to pay up to £20,000 per Quality 
Adjusted Life Year (QALY) gained. However probabilistic sensitivity analysis show the model was 
highly sensitive to overall parameter uncertainty and warrants caution in selecting the optimal 
decision rule on cost-effectiveness grounds. Univariate sensitivity analyses indicate variables such as 
anticoagulation therapy disutility and mortality risks were very influential for driving model results.  
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Conclusion: This represents the first economic model to consider the use of a decision rule for 
restarting therapy for unprovoked VTE patients. Better data are required to predict long-term 
bleeding risks on therapy in this patient group. 
 
Introduction 
Venous Thromboembolism (VTE) is the development of a clot in the veins. The number of deaths 
from VTE in the UK each year is five times greater than deaths from breast cancer, AIDS, and road 
traffic incidents combined [1] and the cost of managing VTE was estimated at around £640 million to 
the UK National Health Service (NHS)[2]. While there are several risk factors that can provoke an 
initial VTE event (such as hormone intake, surgery, trauma, pregnancy and prolonged immobility), 
patients can suffer an initial VTE event without any known trigger (unprovoked).[3-5] Patients with 
an unprovoked VTE have a much higher risk of VTE recurrence than patients whose index VTE event 
has an identifiable cause.[6] The UK National Institute of Health and Care Excellence (NICE)[7] and 
the American College of Chest Physicians (ACCP) [8] recommend at least 3 months anticoagulation 
therapy following a first unprovoked VTE event; after three months of anticoagulation therapy 
following a first unprovoked VTE event, there is clinical equipoise on whether to extend 
anticoagulation therapy.[9-11] Extending anticoagulation therapy reduces the risk of having a 
possible recurrent VTE fatality; but treatment increases the risk of bleeding which can be fatal. 
Balancing the benefit and harm of further treatment requires the identification of risk of recurrent 
VTE and an optimal threshold of VTE risk above which recommending anticoagulation therapy is 
beneficial.  
A previously developed prognostic model estimated an individual patient’s risk of a further 
unprovoked VTE without treatment.[12] A decision rule was developed using this prognostic model 
to stratify patients treatment strategies based on a threshold of VTE recurrence risk (e.g. 5% VTE 
recurrence risk at 1 year post therapy). This study aims to evaluate the cost-effectiveness of a 
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decision rule for restarting therapy in patients after a first unprovoked VTE. The prognostic model 
uses data from D-Dimer testing 30 days after cessation of anticoagulation, however this test is not 
currently part of routine practice. A systematic review did not uncover any economic evaluations 
using a decision rule in this patient group.[12]  
 
Methods 
Model population 
The patient population comprised adult individuals having already completed at least three months 
of anticoagulation therapy in response to their first unprovoked VTE. An initial VTE was defined as 
unprovoked where there was no history in the previous three months of any of the following risk 
factors: major surgery, lower limb trauma, use of combined oral contraceptive pill or hormone 
replacement therapy, pregnancy, significant immobility, or cancer. 
Patients entered the model having already had their D-Dimer level measured thirty days after 
stopping at least three months of anticoagulation therapy. Individual patients were generated from 
patient data (Recurrent VTE Collaborative database)[13] previously used to develop the prognostic 
model.  Each patient had characteristics created by randomly sampling the patient-level data by 
means of a uniform distribution. Patient characteristics comprised age [mean: 61.7 years; standard 
deviation: 15.2], gender [61.8% Male], type of index VTE event (Distal Deep Vein Thrombosis 
(DVT)[9.2%], proximal DVT [58.5%], and Pulmonary Embolism (PE)[32.3%]) and post-anticoagulation 
D-Dimer level [mean: 667.3µg/L; standard deviation: 751.3]. The individual’s risk of a recurrent VTE 
within 12 months was then determined by inputting their newly created characteristics into the 
prognostic model risk equation (Table S1).[12] The risk distribution of the simulated patients is given 
in Table S2. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Model pathways and clinical events 
The economic model compared a strategy of no therapy (usual care) with a number of decision rule 
strategies, where therapy was restarted if the predicted annual risk of VTE recurrence was equal to 
or greater than the given threshold risk (Fig S1). For pragmatic reasons, the arbitrary but clinically 
relevant thresholds were explored in the analyses:1%, 3%, 5%, 7.5% 10%, 12.5%, 15%, 17.5%, 20%, 
22.5%, 25% and a treat-all strategy was also included as a comparator. These specified VTE risks 
were used as different decision rule comparators (example patient predicted risks are given in Table 
S3). No patients initially resumed anticoagulation therapy in the no decision rule comparator. The 
decision rule was applied at the starting point of the model only. Once the decision rule was applied, 
all the patients encountered the same potential pathways in all strategies (Fig 1), with their 
characteristics determining the probabilities of clinical events, costs and utilities.  
In one month, an individual had the probability of experiencing one clinical event: death from other 
causes, recurrent VTE (non-fatal distal or proximal DVT, fatal or non-fatal PE), fatal or non-fatal 
major bleeds (intracranial bleed, gastrointestinal bleed, and other major bleeds). A recurrent VTE 
carried a risk of Post-Thrombotic Syndrome (PTS). 
Other cause mortality was dependent on the current age and gender of the patient and was taken 
from UK life tables.[14] Recurrent VTE risk depended on a patient’s characteristics, time spent in the 
model, previous history of a recurrent VTE event taking place in the model, and treatment status. A 
recurrent VTE could be a PE, distal DVT, or proximal DVT. The recurrent VTE type was assumed to be 
affected by an individual’s initial VTE site. Once a patient suffered a recurrent VTE, they were put on 
anticoagulation therapy for life with therapy cessation only occurring with a later major bleeding 
event. VTE events were assumed to incur a one-off quality of life reduction, with a proportion of 
surviving patients assumed to suffer from severe PTS for life. 
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The risk factors for a major bleed in the model were treatment status and an individual’s’ age if on 
treatment. Major bleeds were split into “gastrointestinal bleeds”, “intracranial bleeds” and “other 
major bleeds.” All major bleeding events had short-term costs and quality of life decrements. In 
addition, an intracranial bleed was assumed to be associated with ongoing costs and a permanent 
quality of life decrement along with a sustained increased lifetime risk of other cause mortality. For 
the “other major bleeds” category, it was agreed by clinical consensus that this heterogenous 
category of bleeds should have the same costs and quality of life decrement as a gastrointestinal 
bleed, for model simplification purposes. 
Any major bleeding event led to discontinuation of anticoagulation therapy. A recurrent VTE in a 
later cycle was assumed to restart therapy. It was assumed that there was no effect of 
anticoagulation therapy on VTE recurrence risk by thirty days post cessation of therapy.  
 
Model type 
A Markov patient-level simulation was developed in TreeAge 2014 (TreeAge software, Williamstown, 
MA, USA) to estimate the cost-effectiveness of using a decision rule for restarting anticoagulation 
therapy versus no anticoagulation therapy (usual care) in patients with a first unprovoked VTE event. 
A Markov model was deemed appropriate as it can represent a clinical situation where patients 
move between health states over a long period of time. A patient-level simulation allows individual 
patients, each with a set of varying characteristics created from patient level data, to be assigned a 
risk of VTE recurrence. Patient characteristics and clinical events which affect subsequent risks were 
remembered in the model with tracker variables. The model was run with a large number of 
simulated patients (50,000) to account for inter-patient variability. 
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A time cycle of one month was selected to represent an assumption that this reflects a period in 
which a single clinical event might occur. Costs, utilities and probabilities were transformed into 
monthly equivalents as per the time cycle length. A half cycle correction was applied to costs and 
effects. The base-case cost-utility analysis was undertaken from a UK National Health Service (NHS)/ 
Personal Social Services (PSS) perspective and considered a lifetime horizon.  
Clinical Parameters 
Parameter estimates and their sources are listed in Table 1. The base case scenario used warfarin as 
the anticoagulation therapy. The risk of a patient’s first recurrent VTE off therapy was calculated 
using the prognostic model for up to three years post D-Dimer measurement (30 days after initial 
therapy cessation). Weak calibration statistics of the prognostic model after three years prompted 
the use of an annual constant risk for the first recurrent VTE event off therapy thereafter. [15] 
Annual risk of a further VTE event after a VTE recurrence was an average of values for patients with 
normal and elevated D-Dimer levels, on and off therapy respectively in the PREVENT trial.[16]  
Resource use and costs 
Costs of therapy and clinical events were included in the model (Table 1). The cost of a D-Dimer test 
was incurred by the decision rule strategies as the D-Dimer information was needed to enact the 
decision rules. All costs were updated to 2012/2013 prices using the Hospital and Community Health 
Services (HCHS) Index.[17]  
Quality of life 
Quality of life (utility) values were assumed to be age related as they enter the model using 
EuroQol–5 Dimensions (EQ-5D) UK normative values.[18] As patients aged in the model, their utility 
score changed to reflect their updated quality of life for their age. Utility values for clinical events 
and being on warfarin therapy (Table ) were multiplied by the age-specific utility to derive quality of 
life reductions for patients experiencing a clinical event and/or on warfarin therapy.  
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Assessment of cost-effectiveness 
The sequential incremental analysis was designed to calculate the cost per quality-adjusted life year 
(QALY) gained for applying a decision rule versus the next most effective option, applying the rules 
of dominance and extended dominance. Cost-effectiveness was assessed in relation to the National 
Institute for Health and Care Excellence (NICE) lower threshold of £20,000 per QALY, where a value 
of £20,000/QALY is judged to be cost-effective.[19] Strategies were compared by increasing 
effectiveness and incremental cost-effectiveness ratios (ICERs) were calculated from the difference 
in costs and effects between a decision rule strategy and the next best alternative. A strategy is said 
to be dominated if they were more expensive and less effective than a comparator. All costs and 
outcomes were discounted at the recommended 3.5%.[20] 
Deterministic Sensitivity Analysis 
To test the robustness of base-case results, a number of deterministic sensitivity analyses were run 
to determine the impact of changing key parameters on results.  
• The model time horizon was restricted to 3 years corresponding to the length of time the 
VTE prognostic model is used.[12] 
• The utility of warfarin therapy was reduced from 0.997 to 0.950 to assess how greater 
disutility associated with anticoagulant treatment affects results.  
• The probability of death from a PE was increased to 30% due to uncertainty amongst clinical 
experts on the true value.  
• The model entry was restricted to patients aged 60 and above, where risk of bleeding on 
therapy is higher.  
• Sub-group analyses were undertaken for index PE patients and index DVT patients, as the 
sub-group of PE patients were at higher risk of recurrence and mortality. 
• Sub-group analyses were undertaken for male and female patients respectively 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
• The lag time in days for d-dimer was adjusted from 30 days to 20 and 40 days respectively 
which changed the risk profile of the patients. 
 
Probabilistic Sensitivity Analysis 
Where available, data were input into the model as distributions to assess parameter uncertainty in 
the form of a probabilistic sensitivity analysis (PSA). The model was rerun with 10,000 simulations 
for each trial of 1,000 simulated patients and the results expressed as cost-effectiveness planes and 
cost-effectiveness acceptability curves (CEACs). 
 
Results 
Base Case Results 
Under base-case assumptions, restarting warfarin therapy for patients with a predicted annual VTE 
recurrence risk of 25% gave the lowest cost per QALY of £1,983 (Table). However, resuming 
anticoagulation therapy for patients with a predicted annual VTE recurrence risk of 17.5% yielded 
the highest number of QALYs while also being considered cost-effective with an ICER of 
£14,980/QALY gained.  
Probabilistic Sensitivity Analysis Results 
The PSA results demonstrate there is considerable uncertainty around the base case results. The 
cost-effectiveness planes (Fig S2-8) show the large uncertainty in the QALY differences for all 
strategies. The majority of the cost-QALY difference values indicate all strategies to be more costly 
than treating no-one, but many of the points were in the north-west quadrant, where a strategy is 
more expensive and less effective compared to treat no-one (dominated). 
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The CEACs, which compared the most cost-effective base case option (17.5%) against several 
strategies (10%,12.5%,15%, 20%, 22.5%, 25%), show that treating those with a one year VTE risk of 
17.5% has a 44.8-73.3% probability of being cost-effective at a willingness to pay threshold of 
£20,000 per QALY gained (Fig S9-15). The results highlight substantial parameter uncertainty even if 
the calculated ICER point estimates for the base-case results appear to be cost-effective. 
Deterministic sensitivity analysis results 
Deterministic sensitivity scenario results are shown in Table . These illustrate that some variables 
were pivotal in changing the direction of model results. Assuming a greater disutility of being on 
warfarin therapy permits the 22.5% and 25% threshold decision rule to be cost-effective.  
Increasing the risk of death from PE had improved the cost-effectiveness of the lower risk decision 
rule strategies compared with no therapy, with the 12.5% decision rule strategy yielding an ICER of 
£11,129/QALY gained. The age profile of patients made a difference to results. Allowing for a patient 
population to be aged 60 and above only (higher bleeding risk on anticoagulation) revealed the 
22.5% threshold option and above to be a cost-effective option, with all other options not cost-
effective. Likewise, model results were sensitive to a patient’s index VTE event type. All decision rule 
strategies of 10% and above were cost effective when the patients’ index event was a PE reflecting 
the high risk nature of such index events. In contrast, the 25% threshold was the only cost effective 
options when the patients’ index event was a DVT. 
Adjusting the lag time had little effect on the cost-effectiveness of the results except for the 15% 
decision rule; this was now cost-effective when the lag time was increased from 20 to 40 days. 
Having a male-only cohort meant the lowest threshold to be cost-effective is the 12.5% while a 
female-only cohort restricted the lowest threshold to be cost-effective to 15%.  
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Discussion 
Principal findings 
The economic evaluation assessed the cost-effectiveness of utilising a decision rule for the 
resumption of anticoagulation therapy in patients with a first unprovoked VTE. The base-case results 
indicate that treating patients with a predicted one year VTE risk of 17.5% and above with warfarin 
could be cost-effective compared to the next most effective option. These VTE risk cut-off points for 
treatment were much higher than what is considered acceptable in the literature.[21]  
However, PSA results suggest great caution must be applied when considering the base case results. 
Above 25% of the iterations showed less QALYs in the restarting anticoagulation decision rule 
strategies compared to the not restarting anticoagulation therapy strategy (“treat no-one”); the 
17.5% decision rule was  the optimal option in less than half the iterations when compared to the 
higher VTE risk thresholds in the CEACs. 
Quality of life on treatment and mortality risk were important determinants in the cost-effectiveness 
results. Incorporating a greater disutility on warfarin therapy changes the results with only the 22.5% 
and 25% VTE risk threshold options remaining cost-effective. Meanwhile, a small change in the 
proportion of PEs that result in death makes restarting anticoagulation therapy at 12.5% even more 
cost-effective. 
Focusing on different subcategories of patients also changes the base-case results. Sensitivity 
analyses suggest that all index PE patients with a predicted VTE recurrence risk of 10% and above 
should be treated with lifelong anticoagulation therapy, likely because these patients were assumed 
to have a higher risk of a recurrent VTE that would be a PE. Conversely, for index DVT patients, the 
only restart anticoagulation option favoured on cost-effectiveness grounds is a one year recurrent 
VTE risk of 25% or higher. The impact of higher bleeding risks from anticoagulation therapy in the 
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older patient population aged sixty and above was not offset by the reduced risk of recurrent VTE at 
the lower risk thresholds strategies. 
Strengths and weaknesses of the analysis 
This is the first economic evaluation to consider using a decision rule to weigh up the advantages 
and disadvantages of resuming anticoagulation treatment in unprovoked VTE patients.  A key 
strength of the analysis is the use of an individual patient simulation which allows a personalised risk 
prediction for hypothetical patients with characteristics drawn from real patient data. This was 
preferable to the more common cohort model with a homogenous set of characteristics as the 
model results were more representative of a realistic patient population.  The modelling method 
lessened the need for a multitude of separate health states as the Markovian lack of memory 
assumption encountered in cohort models was overcome by tracker variables. 
Several simplifying assumptions were needed. The prognostic model used to calculate individual risk 
predictions was applied at 30 days post cessation of anticoagulation therapy which is not clinically 
ideal as some patients will have recurrence in these thirty days. This was due to D-dimer 
measurements being included within the prognostic model as an important predictor improving 
model discrimination, and so stratification of patients into high and low risk groups (as in the 
decision rule examined here).[12] D-dimer measurements were only available post cessation of 
therapy in the original dataset, however there is much interest and potential benefit in the use of D-
dimer measurements on therapy as a predictor.[22] Indeed this would allow immediate treatment 
decisions to be made before cessation of therapy, potentially negating the small number of possible 
recurrent events in the 30 day window from cessation of therapy to use of the decision rule 
evaluated here. The model does not include pulmonary hypertension which could be considered a 
further limitation and its inclusion may lower the risk threshold for treatment.  
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In the absence of data, constant VTE recurrence risks were used beyond three years, after a 
subsequent VTE and on treatment. In practice, recurrent VTE risk is likely to vary by patient 
characteristics. Additionally, the use of the prognostic model for the economic analysis implicitly 
assumes that the risk prediction tool is perfectly accurate. However, there will be a degree of error 
between predictions and reality. For example, the prognostic model was derived from patient level 
trial data and there is an inherent selectivity of patients in trials (e.g. fewer co-morbidities).In 
addition, the course of action on the resumption and cessation of anticoagulation after a major 
bleeding event may differ between patients. In truth, some patients may continue with their 
anticoagulation therapy after a major bleed while others who subsequently go on to suffer a VTE 
may not restart anticoagulation due to their high bleeding risk.  
Only considering a health care perspective was considered in this model, in line with UK national 
guidance, where threshold values of cost-effectiveness are available (£20,000-£30,000 per 
QALY).[19] Cost-effectiveness may differ when using the societal perspective, but it would be 
difficult to determine in what direction. Whilst patient-incurred costs would be higher with 
prolonged treatment with lifelong anticoagulation due to visits for INR tests, productivity losses may 
be higher in where there is a higher risk of clinical events such as DVT, PE and bleeds, or if 
anticoagulation is required due to a further thrombotic event. 
 
Future research 
The sensitivity analyses have shown the large uncertainty underlying many of the parameters and 
their effect on results. Thus, there is a need for robust long-term data on the risk of recurrent VTE in 
unprovoked index VTE patients. The decision rule aims to balance the risks of recurrence and 
bleeding, and as such accurate bleeding risk data is required for the unprovoked population. It is 
likely that similar to the risk of VTE recurrence, the bleeding risk of individuals is highly 
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heterogeneous, and as such a prognostic model similar to that used for predicting patients VTE 
recurrence risk could be invaluable in improving the accuracy of the economic evaluation results.  
Lastly, future research should aim to incorporate on therapy predictors such as D-dimer in 
prognostic models to provide more timely risk predictions useful for clinical practice. 
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Table 1 - Model Parameters 
Parameter 
(distribution type) 
Estimate 
(distribution parameters) 
Source 
Clinical Parameters - -
Annual risk of recurrent VTE off therapy (fixed) Prognostic model equation (see Table 
S1) 
[12] 
Short term 6 month risk of recurrent VTE on 
anticoagulation therapy (beta) 
2.1% (α=27, β=1239) [23] 
Long-term annual risk of VTE recurrence beyond 6 
months on therapy (beta) 
1.3% (α=1, β=78) [24] 
Long-term annual risk of VTE recurrence beyond 3 
years off therapy(beta) 
 
5.0% (α=5, β=95) 
 
 
[15] 
 
Annual risk of further VTE off therapy after 
previous recurrent VTE (beta) 
Off therapy
On therapy 
 
 
12.0% (α=11, β=81) 
5.0% (α=5, β=95) 
 
[16] 
Probability a recurrent VTE is a PE by index event 
(beta) 
Index event DVT
Index event PE 
 
 
0.15 (α=15, β=88) 
0.52 (α=30, β=28) 
 
 
[13] 
Probability of death from PE in the  first month 
(beta) 
0.2 (α=2, β=8) Clinical consensus 
Proportion of recurrent VTEs resulting in severe 
PTS (beta) 
1.1% (α=4, β=345) [25] 
Annual risk of major bleed by age group (beta)           
  Not on therapy
On therapy 
<65
65-74
75+ 
 
0.45%(α=25,β=5593) 
 
 
2.43% (α=23, β= 929) 
3.25% (α=86, β=2554) 
4.37% (α=106, β=2324) 
 
[26] 
 
 
[27]  
Split of major bleeds by bleed type (dirichlet) 
Gastrointestinal bleed
Intracranial bleed
Other major bleed
 
 
 
36.5% 
17.9%  
45.6%  
(α1;α2;α3) =  
(499;245;622) 
 
[28]  
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Risk of death from major bleed (first month) 
(beta) 
Gastrointestinal bleed
Intracranial bleed
Other major bleed 
 
 
18.4% (α=92, β=407) 
32.2% (α=79, β=166) 
10.5% (α=65, β=557) 
 
[28] 
Standardised mortality ratio for after an 
intracranial bleed (Lognormal)1 
2.2 (95% CI 2.0-2.4) [29] 
Unit costs - - 
Pulmonary Embolism (fixed) £1,519 [30]  
Distal Deep Vein Thrombosis (fixed) £732 [30] 
Proximal Deep Vein Thrombosis (fixed) £732 [30] 
12 months warfarin monitoring (fixed) £337 [31] 
Warfarin (4mg per day, 12 months) (fixed) £22 [32] 
Gastrointestinal bleed (fixed) £1,092 [30] 
Other major bleed (fixed) £1,092 Assumed same as GI Bleed
Intracranial bleed: acute cost (gamma) £8,350 
(α=31.0, β=269.4)2 
[33]  
Intracranial bleed: annual cost (fixed) £1,300 [33] 
D-Dimer test £26 [34] 
1.
 A 95% confidence interval is assumed to be ±0.2 of the mean. 
2. α is the shape parameter and β is the scale parameter 
VTE= Venous Thromboembolism, PTS=Post Thrombotic Syndrome, PE= Pulmonary Embolism 
 
Table 2- Utility Values for Health States 
Health state/ 
clinical event 
Median Utility value 
(Inter-Quartile Range) 
Beta 
distribution 
Duration of 
Disutility 
Source 
DVT 0.84 (0.64-0.98) α=2.0, β=0.6 1 month [35]  
PE 0.63 (0.36-0.86) α=1.2, β=0.8 1 month [35] 
Non-fatal  
intracranial bleed 
0.33 (0.14-0.53) α=1.2, β=2.1 Permanent [35]
GI Bleed 0.65 (0.49-0.86) α=1.2, β=0.8 2 weeks [35]
Other Bleeds 0.65 (0.49-0.86) α=1.2, β=0.8 2 weeks Assumed same as GI Bleeds 
Severe PTS 0.82 (0.66-0.97) α=3.0, β=0.9 Permanent [35] 
Warfarin 0.997 (0.953-1.0)1 α=16.4, β=0.3 Treatment length [36] 
1. 10th and 90th percentile reported instead of Inter-Quartile Range (IQR) 
GI Bleed= Gastrointestinal Bleed, DVT= Deep Vein Thrombosis, PTS=Post Thrombotic Syndrome
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Table 3- Cost-effectiveness of using each decision rule sorted by increasing effectiveness (Lifetime time horizon) 
Strategy Mean cost (£) Mean QALYs ICER (Cost/QALY) (£)  
Treat all 5882 10.4134 Dominated 
Decision rule: 1% 5791 10.4223 Dominated 
Decision rule: 3% 5468 10.4522 Dominated 
Decision rule: 5% 5006 10.4897 Dominated 
Treat No one 3284 10.5160 -
Decision rule: 7.5% 4411 10.5309 Dominated
Decision rule: 25% 3324 10.5361 1983 
Decision rule: 22.5% 3347 10.5404 5360 
Decision rule: 20%  3385 10.5427 Extended domination 
Decision rule: 17.5% 3443 10.5468 14980 
Decision rule: 15%  3541 10.5511 22708 
Decision rule: 10%  3962 10.5534 Dominated 
Decision rule: 12.5% 3703 10.5542 53178
ICER= Incremental Cost-Effectiveness Ratio, QALY= Quality-Adjusted Life Year, VTE= Venous Thromboembolism 
Decision rule strategies based on whether to restart warfarin therapy according to a patient’s predicted 1 year risk of a VTE 
recurrence. Strategies are compared with the next best non-dominated option. 
 
Table 4 - Sensitivity Analysis Scenarios 
Strategy Mean 
cost 
(£) 
Mean 
QALYs 
ICER 
(Cost/QALY) 
(£)  
Strategy Mean 
cost (£) 
Mean 
QALYs 
ICER 
(Cost/QALY) 
(£) 
3 year time horizon  Male only patients   
Treat No-one 385 2.2066 - Treat No-one 3520 10.6271 - 
Decision Rule: 25% 395 2.2085 5108 Decision Rule: 25% 3580 10.6666 1509 
Decision Rule: 22.5% 402 2.2090 14520 Decision Rule: 22.5% 3613 10.6764 3378 
Decision Rule: 17.5% 430 2.2097 40182 Decision Rule: 17.5% 3743 10.7019 5085 
Decision Rule: 12.5% 510 2.2107 82797 Decision Rule: 12.5% 4109 10.7352 10975 
    Decision Rule: 10% 4455 10.7471 29022 
     
Higher risk of death 
from PE 
   
Female only patients    
Treat No-one 3163 10.3430 - Treat No-one 2842 9.8863 - 
Decision Rule: 25% 3208 10.3725 1507 Decision Rule: 25% 2856 9.8906 3217 
Decision Rule: 22.5% 3234 10.3802 3447 Decision Rule: 20% 2881 9.8963 4403 
Decision Rule: 17.5% 3332 10.3958 6250 Decision Rule: 17.5% 2906 9.9001 6746 
Decision Rule: 15% 3434 10.4088 7882 Decision Rule: 15% 2948 9.9058 7272 
Decision Rule: 12.5% 3602 10.4238 11129 Decision Rule: 10% 3182 9.9144 27337 
Decision Rule: 10% 3868 10.4327 29850 Decision Rule: 7.5% 3510 9.9176 102125 
        
All patients aged ≥60 
years  
 Lag d-dimer time of 
20 days 
  
Treat No-one 2412 8.3657 - Treat No-one 3376 10.4989 - 
Decision Rule: 25% 2443 8.3771 2767 Decision Rule: 25% 3427 10.5245 1994 
Decision Rule: 22.5% 2462 8.3783 15460 Decision Rule: 17.5% 3575 10.5370 11842 
Decision Rule: 20% 2487 8.3794 22315 Decision Rule: 15% 3690 10.5423 21728 
Decision Rule: 17.5% 2531 8.3805 42386 Decision Rule: 12.5% 3883 10.5459 53213 
Decision Rule: 15% 2601 8.3807 253213   
     
All patients with 
index PE event 
   Lag d-dimer time of 
40 days 
   
No treat 3309 10.1416 - Treat No-one 3227 10.5295 - 
Decision Rule: 25% 3356 10.1842 1105 Decision Rule: 25% 3261 10.5459 2073 
Decision Rule: 22.5% 3384 10.1975 2094 Decision Rule: 22.5% 3280 10.5492 5701 
Decision Rule: 20% 3429 10.2102 3561 Decision Rule: 20% 3314 10.5519 12669 
Decision Rule: 17.5% 3499 10.2229 5479 Decision Rule: 15% 3447 10.5594 17634 
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Decision Rule: 15% 3614 10.2403 6634 Decision Rule: 12.5% 3589 10.5619 58581 
Decision Rule: 12.5% 3799 10.2639 7836   
Decision Rule: 10% 4089 10.2868 12633   
Decision Rule: 7.5% 4589 10.3000 38079     
        
All patients with 
index DVT event 
 Higher warfarin 
disutility   
 
Treat No-one 3165 10.7310  Treat No-one 3284 10.3319  
Decision Rule: 25% 3197 10.7361 6277 Decision Rule: 25% 3324 10.3451 3008 
Decision Rule: 22.5% 3213 10.7365 50891 Decision Rule: 22.5% 3347 10.3466 16217 
ICER= Incremental Cost-Effectiveness Ratio, QALY= Quality-Adjusted Life Year, PE= Pulmonary Embolism, DVT= Deep Vein 
Thrombosis 
Decision rule strategies based on whether to restart warfarin therapy according to a patient’s predicted 1 year risk of a VTE 
recurrence. Dominated strategies (more costly and less effective) are excluded from the table. 
 
 
